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TGF-b/IL-17 ratioAbstract Aim of the work: To investigate the frequency of FoxP3+CD4+CD25+high cells
(Tregs) in rheumatoid arthritis (RA) patients and their association with clinical and radiological
parameters. Also to study the possible relationship between Tregs and TGF-b as an indicator of
Treg function, with IL17 as an indicator of Th17 function and with the ratio between them to throw
light on the imbalance between these two cytokines in RA.
Patients and methods: Forty RA patients and 20 age and sex matched healthy controls were
enrolled in the study. Patients underwent clinical, laboratory and radiographic assessment. The fre-
quency of Tregs was determined by ﬂowcytometry. Serum IL-17 and TGF-b cytokines were ana-
lyzed using ELISA.
Results: The frequency of Tregs was signiﬁcantly decreased among RA patients and with a par-
allel signiﬁcant decrease in the mean ﬂuorescence intensity (MFI) of FoxP3. Both IL-17 and TGFb
were signiﬁcantly increased. Tregs, IL-17 and TGF-b did not correlate with any of the clinical
ﬁndings, laboratory and radiographic scores. TGFb:IL-17 ratio dropped from 15.8 ± 9.6 among
controls to 5.33 ± 5 among patients with mild-to-moderate activity and 2.45 ± 1.8 among patients
with severe activity.
8 D.S. Al-Zifzaf et al.Conclusion: RA patients show a decreased frequency of Tregs that is not associated with clinical
parameters or radiological damage. The ﬁve-fold increase in IL-17 and two-fold increase in
TGF-b prove a disturbance in the balance of the cytokine milieu in favor of inﬂammation and draw
attention to the importance of considering the interplay of the Treg/TH17 cytokine axis in the path-
ogenesis of RA; hence aiming at restoring that balance during treatment.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
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Rheumatoid arthritis (RA) is a chronic autoimmune disease
characterized by synovial inﬂammation and hyperplasia,
autoantibody production, cartilage and bone destruction, and
systemic features, including cardiovascular, pulmonary, psycho-
logical, and skeletal disorders [1]. The pathogenesis of RA is
multifaceted and involves T cells, B cells and the complex inter-
action of many pro-inﬂammatory cytokines [2]. Advances in
understanding the pathogenesis of the disease have fostered the
development of new therapeutics, with improved outcomes [1].
In RA, it is well known that an imbalance between pro- and
anti-inﬂammatory cytokine activities favors the induction of
autoimmunity, chronic inﬂammation and thereby joint
damage. However, it is less clear how cytokines are organized
within a regulatory network [3].
A novel hypothesis has been proposed that the T helper 17
(Th17)/Regulatory T-cell (Treg) imbalance, along with
Th1/Th2 imbalance, may be responsible for the development
and progression of RA [4]. The CD4+ CD25 high regulatory
T-cells are among the most important cells in the immune sys-
tem regulation. They can control autoaggressive T cells and B
cells, which escape negative selection in the thymus. They
block activation and effector functions of autoreactive T cells
maintaining peripheral self-tolerance and preventing the
development of various inﬂammatory diseases through direct
contact with effector immune cells and the secretion of anti-
inﬂammatory cytokines, such as IL-10 and TGF-b1 [5,6].
Tregs are divided into several populations. Naturally occurring
Tregs, which express the forkhead transcription factor
(FoxP3), are found in the thymus and in the peripheral blood,
where they account for 5–10% of CD4+ T cells. FoxP3 is
responsible for the development of Tregs in the thymus. It is
also needed to maintain the suppressive activity of mature
peripheral Tregs and is a speciﬁc molecular marker for Tregs
in the human peripheral blood. Decreased FoxP3 expression
causes conversion of Tregs into effector cells [7,8]. Thus,
FoxP3 expression is crucial for the identiﬁcation of Tregs bear-
ing suppressive activity [9].
It has been reported that Tregs regulate the effector function
of T-helper cells (i.e. Th1, Th2 and Th17 cells) [10]. Th17 subset
of T-helper cells is pro-inﬂammatory; it plays vital roles in host
defense and has been shown to be involved in the pathogenesis
of autoimmune and inﬂammatory diseases primarily by secret-
ing IL-17 which activates numerous cell types involved in the
pathogenesis of RA, including synovial ﬁbroblasts, monocytes,
macrophages, chondrocytes, and osteoblasts [11,12].
It is therefore clear that Th17 and Treg cells have a func-
tional antagonism, in which Tregs act as immunosuppressive
cells and Th17 cells are involved in inducing autoimmunity.
Tregs and Th17 effectors arise in a mutually exclusive fashion.TGF-b plays a complex and intertwined role in inﬂammation,
T cell lineage commitment, antibody generation, immune sup-
pression, and tolerance. TGF-b produced in the immune sys-
tem will suppress the generation of Th17 effector cells and
induce FoxP3+ Tregs and thereby maintain self-tolerance. It
appears that TGF-b is the mediator of Treg’s potent immune
suppression and regulation of cell differentiation [6,13].
Data regarding the number of Tregs in the circulation of
RA patients compared to healthy individuals are inconclusive
and contradictory which caused recent investigations into
Tregs with focus on the balance between Tregs and other
proinﬂammatory T-cell populations such as Th17 cells [14].
The aim of the present study was to investigate the
frequency of FoxP3+CD4+CD25+high cells (Tregs) in
rheumatoid arthritis (RA) patients and their association with
clinical and radiological parameters. Also to study the possible
relationship between Tregs and TGF-b as an indicator of Treg
function, with IL17 as an indicator of Th17 function and with
the ratio between them to throw light on the imbalance
between these two cytokines in RA.2. Patients and methods
2.1. Clinical assessment
The present study is an observational cross-sectional one that
included 40 patients with RA fulﬁlling the new 2010 EULAR/
ACR criteria [15]. Twenty age and sex matched healthy sub-
jects were also included in the study and served as the control
group. Patients were recruited from inpatient and outpatient
clinic of the Internal Medicine Department-Rheumatology
division as well as from the outpatient clinic of Physical Med-
icine, Rheumatology and Rehabilitation Department of Ain
Shams University Hospitals. Written consent was obtained
from all patients after a full explanation of the study which
was approved by the local ethics committee. Patients with
other autoimmune disorders or those receiving any biologic
therapy were excluded from the study.
Patients underwent detailed history taking, thorough general
and musculoskeletal examination. Pain was assessed by a
0–100 mm horizontal visual analogue scale (VAS). 0 indicated
no pain while 100 indicated the worst intolerable pain. Measure-
ment of the 28-joint count of tender and swollen joint with calcu-
lation of the disease activity score (DAS-28) for each RA patient
was done. Patients with score 63.2 were classiﬁed as having low
disease activity, >3.2 to 65.1 were classiﬁed as having moder-
ately active disease while >5.1 denoted very active disease [16].
Functional disability was evaluated using the Health
Assessment Questionnaire (HAQ) to calculate the disability
index (DI). The eight categories assessed by the DI are (1)
FoxP3+T regulatory cells in Rheumatoid arthritis 9dressing and grooming, (2) arising, (3) eating, (4) walking, (5)
hygiene, (6) reach, (7) grip, and (8) common daily activities.
The difﬁculty during each of these acts was assessed as follows:
zero = without any difﬁculty, one = with some difﬁculty,
two = with much difﬁculty and three = unable to do, then
the sum of the categories scores is calculated and divided by
the number of categories. This gives a score in the 0–3 range
[17].
2.2. Laboratory assessment
Seven milliliters of venous blood was drawn under aseptic con-
ditions from each subject which were divided into three tubes:
an ethylene diamine tetra-acetate (EDTA) tube for CBC and
ﬂowcytometric analysis; a plain tube in which blood was left
to clot and samples were then centrifuged and sera were sepa-
rated to be used for assaying CRP, RF, serum IL-17 and serum
TGF-B; and ﬁnally 2 ml into a sodium citrate tube for ESR.
- Complete blood count (Cell Dyne-2700, Abbott Lab.,
USA).
- Erythrocyte sedimentation rate (ESR) using Westergren
method.
- C-reactive protein (CRP) was assessed by latex agglutina-
tion using AVITEX CRP supplied by Omega Diagnostics
Ltd.
- Rheumatoid factor (RF) was detected by the kit supplied
by Biotec Laboratories based on agglutination test using
particles sensitized with human IgG.
2.3. Assessment of T regulatory FoxP3+CD4+CD25high
The frequency of FoxP3+CD4+CD25high was carried out by
direct immunoﬂuorescence technique using Coulter EPICS
XL Flowcytometer system, which was performed on the
peripheral blood of both patients and controls. For each case,
2 tubes were prepared; the test sample and the isotypic control
sample. As for the test sample, 50 lL of whole anticoagulated
blood was lysed using 1 mL lysing Solution (Sigma chemical
co., St. Louis, MO) followed by washing with phosphate buf-
fer saline (PBS). The cells were stained with combinations of
anti-CD25-Phycoerythrin (PE) [eBioscience, USA, clone
(BC96)] and anti-CD4-Fluorescein isocyanate (FITC) [eBio-
science, USA, clone (RPA-T4)]. Samples were incubated in
the dark for 20 min which was followed by washing with
PBS. Cell pellet was resuspended in 0.5 ml of freshly prepared
ﬁxation/permeabilization working solution (eBioscience, USA)
and incubated for 30 min at 4 C in the dark. This was fol-
lowed by washing once with PBS then washing with 1 ml of
1· permeabilization buffer (eBioscience, USA). Ten microliters
of Phycoerythrin-Cy5 (PE-Cy5)-conjugated anti-humanFoxP3
[eBioscience, USA, clone (PCH101)] was added and incubated
for 30 min at 4 C in dark. After washing with PBS, the cells
were resuspended in PBS for analysis. For the isotypic control
sample, the same steps were followed except that instead of
adding anti-CD25-(PE), PE isotypic control (Beckman Coulter
Immunotech, France) was added and instead of adding
(PE-Cy5)-conjugated anti-humanFoxP3, PE-Cy5 isotypic con-
trol (eBioscience, USA) was added. Data acquisition and anal-
ysis were performed on ﬂowcytometry (EPICS XL coulter,France) using SYSTEM II version 3 software with a standard
3-color ﬁlter conﬁguration.
Data interpretation: Lymphocytes were gated via their for-
ward and side scatter properties, and T cells were identiﬁed
based on their expression of CD4. To discriminate between
CD25high T-regs and CD25low activated effector-memory T
cells, we used CD25 expression on non CD4+ cells as an inter-
nal control. They only express intermediate levels of CD25
(CD25low), whereas CD4+ T cells express CD25 with high
(CD25high) or intermediate (CD25low) intensities. Only CD4+
cells expressing CD25 with higher intensities than the internal
control cells were included in the gate for CD25high cells. The
gate for CD25low cells was set to include cells expressing CD25
at levels above those of the isotype control but at lower expres-
sion levels than the CD25high cells. The amount of FoxP3 per
cell [mean ﬂuorescence intensity (MFI)] was calculated in
CD4+CD25high T cell populations.
2.4. Assessment of serum IL-17 and TGF-b
ID ELISA Human IL-17 and TGF-b kits (ID Labs biotech-
nology Inc, Canada) were used for assessment of serum
IL-17 and TGF-b respectively. The method is solid phase
sandwich ELISA (Enzyme-linked immunosorbent Assay).
The concentration of standards was plotted against their opti-
cal densities on a semi-log graph. The concentrations of sam-
ples were read from this graph.
2.5. Radiologic assessment
Plain X-rays were done on both hands and wrist joints. Scoring
was done using the Modiﬁed Steinbrocker scoring method.
This includes the wrist and metacarpophalangeal joints of both
hands. According to the scoring 0 is normal, 1 reﬂects
juxta-articular osteopenia or soft tissue swelling, 2 denotes
the presence of erosions, 3 the presence of erosion and joint
space narrowing and 4 total joint destruction, either lysis or
ankylosis [18]. Total X-ray scoring was done by adding the
score of the 12 joints, where the maximum score is 48.
Musculoskeletal Ultrasound (MSUS) using real time ultra-
sonography was performed by Philips HDI 200 ultrasound
machine with linear 7–12 MHz probe on the wrist and meta-
carpophalangeal (MCP) joints of the hands for detection of
synovitis which is deﬁned as Hypoechoic or anechoic synovial
hypertrophy. Semiquantitative scoring systems were used to
assess both synovial hypertrophy and erosions: for hypertro-
phy, the used scoring system ranges from 0 to 3, where
0 = absence of visible synovial hypertrophy, 1 = mild syno-
vial hypertrophic, 2 = moderate synovial hypertrophy with
bulge above the line of adjacent bone, 3 = marked synovial
hypertrophy with extension to one or more of the diaphyses.
The same scoring system was applied to erosions where
0 = absence of erosions, 1 = mild erosions, 2 = moderate
erosions, 3 = severe erosions. Total US scoring was done by
adding the score of the 12 joints for both hypertrophy and
erosions, maximum score was 72 [19,20].
Statistical analysis: Statistical software package ‘‘SPSS’’
version 9.05 was used. The descriptive data for quantitative
data were expressed as ranges, mean, standard deviation
(SD) and numbers and percentages for qualitative data. Stu-
dent’s t test was used to compare between two independent
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independent groups for nonparametric data, Chi-square test
to compare the qualitative data between different groups and
Pearson’s correlation coefﬁcient, for relationship between dif-
ferent variables in the same group.
3. Results
The current study included forty RA patients (33 females and 7
males). Their ages ranged from 22 to 49 years with a mean of
39.54 ± 7.67 years. Twenty age and sex matched healthy
individuals were included in the study as a control group.
The descriptive data of the patients are shown in Table 1.
Radiological evaluation of patients using X-rays according
to the modiﬁed Steinbrocker scoring method revealed a mean
score of 12 ± 2.9.Musculoskeletal US examination and scoring
conﬁrmed the presence of bony erosions in all of our patients
with a combined ultrasonography score of 13.33 ± 7.26 (hyper-
trophy score 7.04 ± 4.51, erosions score 6.29 ± 3.01) (Fig. 1).
The distribution of FoxP3+CD4+CD25+high cells
(Tregs) revealed a highly signiﬁcant decrease in the frequency
of Treg cells in RA patients compared to healthy controls
(16.86 ± 6.16% and 26.38 ± 14% respectively, p= 0.008) as
well as a highly signiﬁcant decrease in the MFI of FoxP3 on
the surface of patient Tregs (2.37 ± 0.73% and 6.88 ± 7.26%
respectively, p= 0.000) (Figs. 2 and 3).
We assessed the serum levels of TGF-b1 and IL17 as well as
the ratio between them among both RA patients and healthy
controls and signiﬁcant rise in both cytokine levels was found
(Fig. 4). IL-17 showed a ﬁve-fold increase among patients
while TGF-b showed a two-fold increase in serum level as
compared to controls. This resulted in a highly signiﬁcant drop
in the ratio of TGF- b/IL-17 (Table 2).
The serum level of IL17, TGF-b and their ratio did not
correlate with the Treg percentages in the blood of RA patients
nor in controls. We also reported lack of correlation between
Treg percentages in the blood, serum IL-17 and serum
TGF-b with all the laboratory tests and scores of radiographic
assessment of RA joints (both by X-ray and US) (p> 0.05).
To further clarify the signiﬁcance of Treg function and
number among RA, patients were grouped according to their
activity as assessed by the DAS28 score into 2 groups groupTable 1 Clinical and laboratory data of rheumatoid arthritis
(RA) patients included in the study (n= 40).
Variable Mean ±SD
Age (years) 39.54 ±7.67
Disease duration (years) 4.64 ±3.07
VAS pain score 29.43 ±22.12
HAQ score 0.78 ±0.75
ESR 1st hour (mm) 48.78 ±19.55
CRP (mg/l) 10.2 ±12.72
DAS28 score 4.64 ±1.12
Hemoglobin (gm/dl) 12.05 ±1.47
TLC (109/L) 7.31 ±2.39
Lymphocytes count (109/L) 2.13 ±0.60
VAS: visual analogue score, HAQ: health assessment questionnaire,
ESR: erythrocyte sedimentation rate, CRP: C-reactive protein,
DAS28: disease activity score in 28 joints, TLC: total leucocytic
count.1 having mild to moderate disease activity (DAS28 6 5.1)
and group 2 with severe activity (DAS28 > 5.1) (Table 3).
4. Discussion
RA is a chronic inﬂammatory autoimmune disease arising
from a breakdown in self-tolerance, which leads to aberrant
immune responses to autoantigens. Tregs constitute one of
the key mechanisms of self-tolerance and are a major focus
of study in RA in order to design new and improved therapies
to reinstate self-tolerance [21]. IL-17 secreted by Th17 cells and
TGF-b produced by Tregs among others, have opposite
modulatory effects on the inﬂammatory process, although they
do not exert mutual inhibitory effects. In the presence of IL-6,
TGF-b contributes to the development of a Th17 response.
Whereas TGF-b is a potent modulator of the immune
response, IL-17 is able to reactivate the inﬂammatory process,
including the induction of inﬂammation. Thus, the amount of
TGF-b, as well as the presence or absence of proinﬂammatory
cytokines, determines the balance between the expression of
transcription factors such as RORct and FoxP3 and, conse-
quently, whether the immune response proﬁle will be Th17
or Treg [22].
It has been suggested that the balance between Th17 and
Treg cells may be abnormal in RA and this imbalance may
play a pivotal role in RA pathogenesis because predominant
Th17 cells can exert strong pro-inﬂammatory response by
producing IL-17 and impaired Tregs, partly due to the
cytokine microenvironment, cannot control this immune
response [23].
In this study, ﬂowcytometric analysis in RA patients
revealed a highly signiﬁcant decrease in the frequency of circu-
lating FoxP3CD4+CD25high Tregs as compared to healthy
controls (p< 0.001). This result was in agreement with other
groups [24–27]). The exact mechanisms that reduce the level
of Tregs are not clear. It was suggested that regulatory cells
are recruited to sites of inﬂammation in an attempt to suppress
disease, resulting in a relative reduction in the peripheral blood
population [24]. Reports of a higher number of Tregs present
in synovial ﬂuid than that in the peripheral blood in RA
patients support this explanation. Tregs accumulated in
inﬂamed joints express high levels of surface and intracellular
CTLA-4, GITR, OX-40, and FoxP3 [28]. Moreover, Tregs
were found to display increased tendency to undergo sponta-
neous apoptosis in active RA [29,30]. Chavele and Ehrenstein
proposed that in an inﬂammatory condition like RA, it is quite
possible that Tregs in the presence of the different proinﬂam-
matory cytokines will become unstable and convert to patho-
genic T-cells [14]. This decline in regulatory T-cell numbers
may pre-dispose to persistent auto-immune diseases including
RA [24].
Contrary to our results there are reports of increased Tregs
in RA peripheral blood [31,32] but in their research they
assessed different CD4+CD25+ T cell subtypes (including
CD4+ T-cells expressing low levels of CD25 and those
expressing FoxP3 and those not expressing it) which could
account for the discrepancy in the results.
In our study we reported lack of correlation between Treg
percentages in the blood, with all the clinical ﬁndings, labora-
tory tests and radiographic assessment of RA joints (both by
Figure 1 Four examples of synovial hypertrophy and bone erosions in RA patients. A: longitudinal view of the DIP joint showing
moderate synovial hypertrophy (score 2) (vertical arrow) and marked erosions (score 3) (slanting arrows). B: longitudinal view of the PIP
joint showing marked synovial hypertrophy (score 3) (horizontal arrows) and mild erosions (score 1) (slanting arrow). C: longitudinal view
of the MCP joint showing marked synovial hypertrophy (score 3) (horizontal arrow) and mild erosions (score 1) (slanting arrow). D:
longitudinal view of the MCP joint showing moderate synovial hypertrophy (score 2) (left arrow) and moderate erosions (score 2) (right
arrow). N.B. Red arrows = Tendons.
Figure 2 A ﬂow histogram of a patient from the RA case group. The percentage of CD4+ from the lymphocytes is 40% represented as
C region. The percentage of CD4+CD25+ from CD4+ T-cells is 5.01% represented as E2 region. The percentage of CD4+CD25high from
CD4+ T-cells is1.34% represented as F region. The percentage of FoxP3CD4+CD25high from CD4+ T-cells is 64.5% represented as D
region.
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previous study which stated that the frequencies of synovial
CD4+ CD25high T cells in patients with RA was notcorrelated with clinical parameters such as disease duration,
the presence of rheumatoid factor, the level of CRP and the
presence of erosions. These data suggest that the presence of
Figure 3 Median percentages of FoxP3CD4+CD25high Tregs (Left) and mean ﬂuorescence intensity (MFI) on Tregs (Right) among
control and rheumatoid arthritis cases.
Figure 4 Comparison between control and cases as regards
median values of serum IL-17 and serum TGF-b.
Table 2 Comparison between the controls and rheumatoid arthriti
Cytokine mean ± SD Controls (n= 20) RA patien
IL17 (ng/mL) 2.01 ± 2.7 10.9 ± 4.9
TGF-b1 (ng/mL) 16.4 ± 5.8 35.5 ± 10
TGF: IL17 ratio 15.8 ± 9.6 4.8 ± 4.7
IL17: interleukin-17, TGF: transforming growth factor.
12 D.S. Al-Zifzaf et al.CD4+CD25+ T cells in the rheumatoid synovium is a func-
tion of the disease but unrelated to treatment, clinical course
and disease activity [31]. Han et al. have also shown that no
relationship exists between the number of CD4+CD25high
T cells and RA disease activity [32].
The forkhead box P3 (FoxP3) transcription factor is now
considered the most speciﬁc marker of Tregs as it is essential
for both Treg cell development and function [33]. Assessing
MFI of FoxP3 in Tregs showed a highly signiﬁcant decrease
among RA patients than healthy controls (p< 0.001) which
agrees with the reports of other groups [34,27]. This decline
in FoxP3 expression could explain the depressed suppressive
capacity of T-reg cells of RA patients as FoxP3 ampliﬁes
and stabilizes molecular features of Treg precursor cells, bene-
ﬁcial to their function and maintenance, and reverses features
harmful to Treg cell function. Decreased FoxP3 expression
enhances autoimmune responses by weakening the suppressive
function of Tregs and converting them into effector cells
[35,8,36]. This result was not in agreement with Han et al.
who showed that the FoxP3+ cells from RA patients
expressed more FoxP3 per cell when compared to healthy con-
trols [32].
The production of IL-17 plays a crucial role in the develop-
ment of cartilage and bone lesions as IL-17 can promote
inﬂammation by inducing the production of pro-inﬂammatory
mediators, including cytokines, chemokines and other media-
tors of bone and cartilage destruction such as metalloprotein-s (RA) cases as regards the assessed cytokines levels.
ts (n= 40) Z p Signiﬁcance
4.27 0.000 HS
.7 4.36 0.000 HS
3.37 0.001 HS
Table 3 Comparison between mild-to-moderate and severe disease activity in rheumatoid arthritis patients as regards Treg
percentages, MFI of FoxP3, IL17 serum level, TGF-b serum level and the TGF/IL17 ratio.
Variable mean ± SD Disease activity Z p Sig.
Mild-to-moderate (n= 31) Severe (n= 9)
Tregs from CD4+ T-cells (%) 16.5 ± 5.8 18.8 ± 8.5 0.39 0.697 NS
FoxP3 MFI on Tregs (%) 2.3 ± 0.8 2.6 ± 0.5 1.14 0.254 NS
Serum IL17 (ng/mL) 10.2 ± 4.5 14.2 ± 6.1 1.73 0.083 NS
Serum TGFb1 (ng/mL) 37.2 ± 10.6 26.5 ± 5.8 2.23 0.026 S
TGF/IL17 ratio 5.3 ± 5 2.5 ± 1.8 2.06 0.039 S
Treg: regulatory T cells, MFI: mean ﬂuorescence intensity, IL17: interleukin-17, TGF: transforming growth factor.
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in IL-17 serum level among RA patients. These results are in
accordance with the ﬁndings of other groups [38–43]. Some
studies have shown that plasma IL-17 levels in RA patients
did not differ from those in OA patients or healthy controls
[35,44,45]. Though IL-17 serum level did not correlate with
the DAS28 score yet it was signiﬁcantly higher among severely
active patients as compared to patients with moderate activity
which agrees with the reports of other groups [41].
The major source of TGF-b1 in the immune system is
FoxP3-expressing regulatory T cells, Local TGF-b1 activation
seems to be necessary for both immune suppression and Th17
generation [46,47]. TGF-b1 has been shown to induce FoxP3,
which is responsible for the suppression activity of Tregs [47].
We reported a signiﬁcant increase in the serum level of
TGF-b1 among rheumatoid patients as compared to controls.
Similar ﬁndings were reported by other groups [48,49].
TGF-b1 did not correlate with clinical or radiological ﬁndings.
This disagrees with the ﬁndings of Mieliauskaite et al., who
reported correlations between TGF-b1 levels and radiologi-
cally deﬁned joint damage determined by the Steinbrocker
scoring system.
Although TGF-b1 is well known for its immune-suppres-
sive and anti-inﬂammatory properties, it is also capable of
promoting inﬂammation. TGF-b1 is expressed abundantly in
the rheumatoid synovium and is thought to contribute to the
progression of inﬂammation and joint destruction in RA [50].
In the absence of IL-6, TGF-b1 combined with IL-10,
promotes the differentiation of naive T-cells to Tregs, which
in turn produce IL-10 and TGF-b1, exerting a nonspeciﬁc
immunosuppressive effect that can inhibit Th17, Th1, and
Th2 cells, In mice, in contrast, combination of TGF-b1 with
IL-6 induces naive T-cells to differentiate into Th17 cells [8,51].
Among RA patients both cytokines increased in spite of the
decrease in the percentage of Tregs. IL-17 increased over ﬁve
folds while TGF b increased a little over 2 folds tilting the
balance of these two cytokines in the favor of inﬂammation.
This could be a result of the compensatory increase in Treg cell
function in an attempt to overcome the systemic immune stim-
ulation in RA patients despite their relative deﬁciency in the
peripheral circulation.
Upon comparing the results of our patients according to
their activity level as assessed by the DAS28 we found a rise
in serum IL-17 level that did not reach statistical signiﬁcance
accompanied by a signiﬁcant decrease in serum TGFb1 which
resulted in a signiﬁcant difference in the TGFb1: Il-17 ratio.
The ratio dropped from 15.8 ± 9.6 among controls to
5.33 ± 5.0 among patients with mild to moderate activityand further decreased to 2.45 ± 1.8 among patients with
severe activity. This reﬂects a shift toward a dominance of
IL-17 as a pro-inﬂammatory cytokine secreted by Th17 cells
over the suppressive cytokine TGFb1 secreted by Tregs.
In conclusion, RA patients show decreased frequency of
Tregs that is not associated with clinical parameters or with
radiological damage. The IL-17 ﬁve fold increase and two fold
increase in TGF-b prove a disturbance in the balance of the
cytokine milieu in the favor of inﬂammation and draw atten-
tion to the importance of considering the interplay of the
Treg/TH17 Cytokine Axis in the pathogenesis of RA and
hence aiming at restoring that balance during treatment.
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